Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $10
Organon & Is Maintained at Equal-Weight by Morgan Stanley
Organon Analyst Ratings
Evercore Downgrades Organon & Co(OGN.US) to Hold Rating
BofA Securities Maintains Organon & Co(OGN.US) With Sell Rating, Cuts Target Price to $10
Research Alert: Mixed Q1 Results, Full-year 2025 Revenue Decline Guidance Maintained
Piper Sandler Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $24
TD Cowen Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $15
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $15
BofA Securities Maintains Organon & Co(OGN.US) With Sell Rating, Announces Target Price $11
BofA Securities Adjusts Price Target on Organon to $11 From $15, Maintains Underperform Rating
Cautious Hold Rating on Organon Amid Updated Financials and Market Conditions
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $15
Organon & Is Maintained at Equal-Weight by Morgan Stanley
Organon Analyst Ratings
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $24
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Cuts Target Price to $24
Goldman Sachs Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $19
Organon & Is Maintained at Equal-Weight by Morgan Stanley
Organon Analyst Ratings